. Pour and L. Chevalier, Caractérisation moléculaire de l'EGFR dans les cancers bronchiques non à petites cellules : étude prospective comparative des technologies NGS et automate Idylla, Annales de pathologie, 2020.

, Références [1] Rapport interactifLes cancers en France -édition, 2017.

D. Sur,

N. E. Hynes and G. Macdonald, ErbB receptors and signaling pathways in cancer, Curr Opin Cell Biol, vol.21, pp.177-84, 2009.

W. Pao and N. Girard, New driver mutations in non-small-cell lung cancer, Lancet Oncol, vol.12, pp.175-80, 2011.

C. B. Meador, C. M. Micheel, M. A. Levy, C. M. Lovly, L. Horn et al., Beyond histology: translating tumor genotypes into clinically effective targeted therapies, Clin Cancer Res, vol.20, pp.2264-75, 2014.

T. S. Mok, Y. Wu, S. Thongprasert, C. Yang, D. Chu et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, vol.361, pp.947-57, 2009.

L. Y. Tan, S. M. Walker, T. Lonergan, N. E. Lima, A. V. Todd et al., Superior Multiplexing Capacity of PlexPrimers Enables Sensitive and Specific Detection of SNPs and Clustered Mutations in qPCR, PLOS ONE, vol.12, p.170087, 2017.

M. Ilie, C. Butori, S. Lassalle, S. Heeke, N. Piton et al., Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer, Oncotarget, vol.8, pp.103055-62, 2017.

Q. Breton, I. Valo, F. Benallègue, A. Morel, and V. Verrièle, Influence de la cellularité tumorale dans la recherche des mutations des cancers du poumon : expérience du centre Paul Papin (Angers), 2015.

, ©Mutations de l'EGFR dans le cancer du poumon : mise en évidence d'une cible moléculaire permettant un accès spécifique aux thérapies ciblées, 2010.

P. M. Forde and D. S. Ettinger, Managing acquired resistance in EGFRmutated non-small cell lung cancer, Clin Adv Hematol Oncol HO, vol.13, pp.528-560, 2015.

R. M. Jotte and D. R. Spigel, Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance, Cancer Med, vol.4, pp.1621-1653, 2015.

K. Nguyen, S. Kobayashi, and D. B. Costa, Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway, Clin Lung Cancer, vol.10, pp.281-290, 2009.

E. L. Stewart, S. Z. Tan, and G. Liu, Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations -a review, Transl Lung Cancer Res, vol.4, pp.67-81, 2015.

T. Jiang and C. Zhou, Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor--resistant non-small cell lung cancer, Transl Lung Cancer Res, vol.3, pp.370-372, 2014.

K. S. Thress, C. P. Paweletz, E. Felip, B. C. Cho, D. Stetson et al., Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M, Nat Med, vol.21, pp.560-562, 2015.

L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, R. Rosovsky et al., Implementing multiplexed genotyping of non-smallcell lung cancers into routine clinical practice, Ann Oncol, vol.22, pp.2616-2640, 2011.

F. Skoulidis, M. E. Goldberg, D. M. Greenawalt, M. D. Hellmann, M. M. Awad et al., STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov, Internet], 2018.

, Genetically Informed Cancer Medicine -My Cancer Genome

D. Sur,